C Difficile Infection

Clinical trials consistently demonstrate that fecal microbiota treatment is an effective treatment strategy for recurrent CDI, yet standardization practices vary.

Perhaps surprisingly, patients admitted during periods of higher occupancy had 15% lower odds of contracting Clostridium difficile infection.

The double-blind, placebo-controlled, parallel-group study that aims to observe linaclotide 290 mcg in 600 adult patients with IBS-C in the US.

Researchers compared the cost-effectiveness of vancomycin, fidaxomicin, and bezlotoxumab with vancomycin as treatments for treating the first recurrence of Clostridium difficile infection.

Fecal microbiota transplant and oral metronidazole are equally effective and tolerated for C. difficile treatment.

Researchers have correlated asthma, allergic rhinitis, and atopic dermatitis to the condition.

An epidemiologist shares his knowledge about Clostridium difficile prevention and control.